Healthcare
Quote through 2026-08-04T13:30:00Z · Delayed
Quote synced 2026-08-05T23:29:40.077762Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-05T03:07:34.593709Z
Fundamentals through 2026-05-04 · Current
Fundamentals synced 2026-08-05T20:32:33.140342Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:55:47.392589Z
Ownership through 2026-05-04 · Current
Ownership synced 2026-08-05T20:32:33.140342Z
Short interest: Missing
Short interest synced 2026-08-05T20:32:33.140342Z
News: Missing
News synced 0001-01-01T00:00:00Z
Company profile: Delayed
Company profile synced 2026-05-06T21:56:53.846237Z
Regular-session price
Offline$139.00
+0.00% regular session
1Y Change
+99.51%
Window
Aug 5, 2025 → Aug 3, 2026
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
0.0%
1M
+73.7%
6M
+15.0%
YTD
+17.0%
1Y
+99.5%
Coverage: 250 bars · Aug 5, 2025 → Aug 3, 2026
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
AAVXF is 78.86 pts ahead over the shared 1Y window.
AAVXF had 37.29 pts deeper max drawdown than SPY.
AAVXF beat SPY in 2 of 2 calendar years shown and trailed in 0.
AAVXF
+99.51%
Normalized return
SPY
+20.65%
S&P 500
Excess Return
+78.86 pts
Relative to SPY
AAVXF Max Drawdown
-46.42%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for AAVXF and SPY.
| Year | AAVXF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +16.95% | +12.67% | +4.28 pts | AAVXF |
| 2025 | +70.59% | +9.40% | +61.19 pts | AAVXF |
Financials
Annual, quarterly, and TTM views with reported currency, units, source, download, and filing context.
Period
Units
Reported currency
EUR
Source
FMP
Last checked
Apr 7, 2026
FY Revenue
€0.0
-100.0% YoY
FY Net Income
-€336.0M
-90.6% YoY
Free Cash Flow
-€162.2M
-4.8% YoY
Revenue Growth
-100.0%
EPS Growth
-73.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
EUR
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.04M | 4.58M | 4.62M | 10.8M | 0M |
| Gross Profit | -0.12M | 4.51M | 4.49M | 10.8M | -1.07M |
| Operating Income | -52.2M | -56.6M | -127M | -173M | -251M |
| EBITDA | -38.7M | -53.3M | -133M | -172M | -249M |
| Net Income | -41.4M | -69.8M | -148M | -176M | -336M |
| EPS (Diluted) | -- | -- | -- | -- | -- |
Balance sheet
EUR
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.7M | 26.9M | 252M | 144M | 516M |
| Total Assets | 110M | 73.4M | 327M | 205M | 584M |
| Total Liabilities | 81.6M | 71.5M | 131M | 165M | 129M |
| Shareholder Equity | 28.8M | 1.88M | 196M | 40.6M | 455M |
| Total Debt | 53.4M | 46.7M | 59M | 97.4M | 32.1M |
| Net Debt | -7.25M | 19.8M | -193M | -46.9M | -484M |
Cash flow positioning
2025
Operating Cash Flow
162M
-5.2% YoY
Capital Expenditures
0.14M
+77.9% YoY
Free Cash Flow
162M
-4.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-165.2%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.